E56-C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy- Dr. Kourous Rezaei

Dr. Kourous Rezaei reviews the results of the GATHER1 trial on complement C5 inhibition for slowing down progression of geography atrophy in dry AMD. References article: Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586. doi: 10.1016/j.ophtha.2020.08.027. Epub 2020 Sep 1. PMID: 32882310.

Episode metadata supplied by the publisher feed · Published Dec 24, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

E56-C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy- Dr. Kourous Rezaei

0:00 30:18

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Retina Channel Podcast?

This episode is 30 minutes long.

When was this The Retina Channel Podcast episode published?

This episode was published on December 24, 2021.

Can I download this The Retina Channel Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!